01—Abstract
Summary
Summary of the 8-K filed January 23, 2025. Cited figures are marked; the original filing is the authoritative source.
Amcor plc (AMCR) filed an 8-K on January 23, 2025 to announce a milestone in its previously announced all-stock combination with Berry Global Group (BERY).
The companies filed the definitive joint proxy statement/prospectus, which the SEC declared effective the same day, and both companies began mailing it to shareholders on or about January 23. Amcor and Berry shareholder meetings are both scheduled for February 25, 2025, with the transaction expected to close around the middle of calendar 2025. The filing itself is primarily procedural: it is furnished under Item 7.01 (Regulation FD) and contains no new financial results.
The press release emphasizes the investment case management is presenting. The companies cite approximately $650 milliona of identified cost, growth and financial synergies by the end of the third year after closing, including roughly $530 million of run-rate pre-tax cost synergies, and about $280 million of one-time working capital cash benefits offset by roughly $280 million of pre-tax costs to achieve. Management also projects combined annual cash flow of over $3 billion, a commitment to an investment-grade balance sheet, and over 35% adjusted cash EPS accretion to Amcor shareholders relative to its LTM September 30, 2024 standalone EPS, with estimated long-term shareholder value creation rising from 10-15% to 13-18% per annum.
Investors should treat the synergy and accretion figures as management estimates. The release includes extensive forward-looking and non-GAAP caveats, and the synergy estimates are explicitly described as preliminary and subject to change.
Key risks include shareholder and regulatory approval, integration execution, customer and personnel retention, and litigation. Investors should review the joint proxy statement/prospectus for full terms, risk factors and governance details before the February 25 votes.
02—Key points
Key Highlights
- Definitive joint proxy statement/prospectus filed and S-4 registration declared effective by the SEC on January 23, 2025; mailing to shareholders began on or about that date.
- Amcor and Berry shareholder meetings both scheduled for February 25, 2025; record date was January 17, 2025.
- Expected transaction completion in the middle of calendar 2025, subject to shareholder and regulatory approvals.
- Estimated ~$650M of identified cost, growth and financial synergies by the end of year three, including ~$530M run-rate pre-tax cost synergies.
- Management projects over 35% adjusted cash EPS accretion (run-rate, year three, versus Amcor's LTM Sept. 30, 2024 standalone EPS) and combined annual cash flow above $3B.
- Both boards unanimously recommend the transaction; management targets an investment-grade balance sheet post-closing.
- Filing is procedural under Item 7.01 and contains no new financial results; synergy and accretion figures are non-GAAP, forward-looking estimates.
03—Questions
Frequently Asked Questions
When do shareholders vote on the Amcor-Berry transaction?
Both the Amcor extraordinary general meeting and the Berry special meeting are scheduled for Tuesday, February 25, 2025. The record date for both was January 17, 2025.
When is the transaction expected to close?
The companies expect completion around the middle of calendar year 2025. The dates are subject to change, and the companies provide no assurance that completion will occur within that timeframe or at all.
What synergies are management projecting?
Management estimates about $650 million of identified cost, growth and financial synergies by the end of the third year after closing. This includes roughly $530 million of annual run-rate pre-tax cost synergies, about $60 million of run-rate financial savings, and about $60 million of run-rate pre-tax earnings from growth synergies. Approximately $280 million of one-time working capital cash benefits are expected, offset by roughly $280 million of pre-tax costs to achieve.
What are the main risks to completing the deal?
Key risks include failure to satisfy closing conditions such as shareholder and regulatory approvals on a timely basis, integration challenges, the potential failure to realize anticipated benefits, unexpected costs, litigation, disruption to management, and the loss of key personnel or customers. The release also notes the possibility of termination of the merger agreement.
How reliable are the accretion and synergy estimates?
They are management estimates that rely on many assumptions and preliminary analysis, and they are not GAAP measures. The company states they may prove inappropriate due to economic conditions, packaging industry trends, competition and business decisions. Investors should review the joint proxy statement/prospectus for detailed risk factors before relying on them.
04—Continue